Researchers are genetically sequencing the virus in hopes of one day developing better prevention and treatment.
Research into testing and vaccination for both the oral and genital forms of the herpes simplex virus (HSV) continues, but the prevalence and evolution of the virus add to the challenge of this task.
Thomas Quinn, MD, a professor of medicine at Johns Hopkins University School of Medicine who is also an international researcher with the NIH’s National Institute of Allergy and Infectious Diseases, has been working to analyze the genetic diversity of HSV-2 (genital herpes) strains from around the world.
Dr Quinn has been conducting research in East Africa for 30 years and is a senior author of 2 studies on sequencing the HSV genome that appeared in the August issue of the Journal of Virology.
Thomas Quinn, MD
HSV was first genetically sequenced using only European patient strains, and the resulting diagnostic test was developed to identify sequences common to those strains, according to a press release from Johns Hopkins. Scientists have long suspected that the glycoproteins present in African patients who are HSV-positive might differ from those in patients in the United States and Europe.
Related: More teens lack HSV-1 antibodies
The researchers note that HSV-2 is a causative agent of genital and neonatal herpes. Therefore, knowledge of its DNA genome and genetic variability is central to prevention and treatment of genital herpes. However, until now, only 2 full-length HSV-2 genomes had been reported. The researchers’ new analysis of additional genomes will facilitate research aimed at vaccine development, diagnosis, and the evaluation of clinical manifestations and transmission of HSV-2. This information will also contribute to the understanding of HSV evolution, they claim.
Read: Potential vaccine tested on mice
“We really can’t predict when we will have a safe and effective vaccine against HSV-2,” Dr Quinn told Contemporary OB/GYN in an email. “Several vaccines have been made and evaluated but did not demonstrate high efficacy in the volunteers. Another large trial is currently under way and we will have to see how effective that will be.
“Developing an effective vaccine is tough due to the high frequency of HSV-1 infections in many people that seem to interfere with the overall immunogenicity of the vaccine,” he explained. “But we keep on trying with new vaccines that are developed thanks to the new molecular information on herpes.”
Newman RM, Lamers SL, Weiner B, et al. Genome sequencing and analysis of geographically diverse clinical isolates of herpes simplex virus 2. J Virol. 2015;89:8219–8232.
Advancing obstetric and gynecologic surgery through robotic innovation
April 30th 2024Explore how robotic surgery revolutionizes obstetric and gynecologic procedures, offering enhanced precision, reduced complications, and improved patient outcomes, while also examining challenges and future prospects in the field.
Read More
Unlocking placenta accreta spectrum with single-cell gene targets
April 18th 2024Discover how cutting-edge single-cell RNA sequencing unveils molecular insights into placenta accreta spectrum disorders, potentially revolutionizing diagnostics and treatments for this life-threatening pregnancy complication.
Read More
Excessive gonadotropins in IVF: Effects on mosaicism and live birth
April 12th 2024A recent study revealed a correlation between high doses and prolonged duration of exogenous gonadotropin use during in vitro fertilization and increased embryonic mosaicism alongside diminished live birth rates, prompting reconsideration of dosage and duration protocols.
Read More
Maternal history linked to uterine fibroid risk in Black women
April 11th 2024Delve into the findings of a recent study revealing the heightened risk of developing uterine fibroids among Black women with a maternal history of the condition, shedding light on crucial implications for patient care and advocacy.
Read More